This study demonstrates an additional advantage of TLR3 adjuvant for direct therapeutic application to tumor cells: TLR3-targeted therapy may be of benefit to cancer patients by acting on both immune cells and tumor microenvironment. This evidence concerns the gene TLR3 and neoplasm.